Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure

Clinical Autonomic Research

Volumn 14, Issue 6, 2004, Pages 363-368

  Goldstein, David S ^a   Holmes, Courtney ^a   Kaufmann, Horacio ^b   Freeman, Roy ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Autonomic failure; Dihydroxyphenylglycol; DOPS; Norepinephrine; Sympathetic nervous system

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; CATECHOL; FLUDROCORTISONE; NORADRENALIN; THREO 3,4 DIHYDROXYPHENYLSERINE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; MATHEMATICAL COMPUTING; SHY DRAGER SYNDROME; SUPINE POSITION; VENOUS BLOOD;

AGED; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CATECHOLAMINES; CHRONIC DISEASE; DIET; DROXIDOPA; FEMALE; HALF-LIFE; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE;

EID: 13244281685     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10286-004-0221-z     Document Type: Article

References (19)

1. Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108:724-728
2. Goldstein DS, Polinsky RJ, Garty M, Robertson D, Brown RT, Biaggioni I, Stull R, Kopin IJ (1989) Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 26:558-563
3. Polinsky RJ, Kopin IJ, Ebert MH, Weise V (1981) Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 31:1-7
4. Ziegler MG, Lake CR, Kopin IJ (1977) The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 296:293-297
5. Mathias CJ (1995) The classification and nomenclature of autonomic disorders - ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 5:307-310
6. Holmes C, Eisenhofer G, Goldstein DS (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Applic 653:131-138
7. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429-436
8. Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739-744
9. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 52:718-723
10. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43:367-371
11. Goldstein D, Horwitz D, Keiser HR, Polinsky RJ, Kopin IJ (1983) Plasma 1-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. J Clin Invest 72:1748-1758
12. Grossman E, Chang PC, Hoffman A, Tamrat M, Kopin IJ, Goldstein DS (1991) Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol 260:R946-R952
13. Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336:696-702
14. Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11:3-20
15. Crout JR, Sjoerdsma A (1964) Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 43:94-102
16. Spector S, Tarver J, Berkowitz B (1972) Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels. Pharmacol Rev 24:191-202
17. Goldstein DS (2003) Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2:669-676
18. Cannon WB (1939) A law of denervation. Am J Med Sci 198:737-750
19. Davies B, Sudera D, Sagnella G, Marchesi-Saviotti E, Mathias C, Bannister R, Sever P (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69:779-784